Jody LoMenzo Named Director, Investor Relations and Corporate Communications
31 Octobre 2006 - 2:15PM
Business Wire
Insmed, Inc. (NASDAQ:INSM) announced today that Jody M. LoMenzo has
joined the company to serve as Director, Investor Relations and
Corporate Communications. Over the course of her professional
career, Ms. LoMenzo has served in senior communications roles for
Fortune companies, start-ups, and non-profits, including: the
medical-surgical division of McKesson Inc. as marketing
communications director; United Dominion Realty Trust, as director
of investor relations and corporate communications; Infineon
Technologies (White Oak Semiconductor) as communications director;
and as administrative director for marketing and public relations
at Bon Secours Richmond Health System. Ms. LoMenzo also has
experience on the agency side, working as director of strategic
communications for the public relations division of The Martin
Agency. She owned and operated her own communications strategy
firm, working with healthcare clients in biotechnology and
pharmaceuticals to introduce and promote new drugs. Of note, her
work with Genentech for the launch of tPA, SmithKline for its
Hivagen test, Amgen for Neupogen, Fujisawa for Ganite,
BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and Lederle
for Suprax. Ms. LoMenzo began her professional career in
television, working in New York City, as a news editor for ABC-TV�s
Good Morning America and as associate producer at CBS News. She
received an Emmy nomination while at WABC-TV for her work as
special projects producer. A graduate of New York University, she
resides in Richmond. About Insmed Insmed is a biopharmaceutical
company focused on the development and commercialization of drugs
for the treatment of metabolic diseases and endocrine disorders
with unmet medical needs. For more information, please visit
www.insmed.com. Forward Looking Statements Statements included
within this press release, which are not historical in nature, may
constitute forward-looking statements for the purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements regarding the pending litigation and
or future ability to conduct our business as now conducted and as
it is currently proposed to be conducted. Such forward-looking
statements are subject to numerous risks and uncertainties,
including but not limited to the uncertainty of the outcome of any
litigation with Tercica, the risk that product candidates may fail
in the clinic or may not be successfully marketed or manufactured,
the company may lack financial resources to complete development of
product candidates or the FDA or other regulatory agencies may
interpret the results of our studies differently than we have. We
can give no assurances that we would be successful in any
litigation or that such litigation would not have a material
adverse effect on our business, financial condition and results of
operation. Furthermore, we may not be able to afford the expense of
defending against such a claim. As a result of these and other
risks and uncertainties, actual results may differ materially from
those described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended. Insmed, Inc. (NASDAQ:INSM)
announced today that Jody M. LoMenzo has joined the company to
serve as Director, Investor Relations and Corporate Communications.
Over the course of her professional career, Ms. LoMenzo has served
in senior communications roles for Fortune companies, start-ups,
and non-profits, including: the medical-surgical division of
McKesson Inc. as marketing communications director; United Dominion
Realty Trust, as director of investor relations and corporate
communications; Infineon Technologies (White Oak Semiconductor) as
communications director; and as administrative director for
marketing and public relations at Bon Secours Richmond Health
System. Ms. LoMenzo also has experience on the agency side, working
as director of strategic communications for the public relations
division of The Martin Agency. She owned and operated her own
communications strategy firm, working with healthcare clients in
biotechnology and pharmaceuticals to introduce and promote new
drugs. Of note, her work with Genentech for the launch of tPA,
SmithKline for its Hivagen test, Amgen for Neupogen, Fujisawa for
Ganite, BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and
Lederle for Suprax. Ms. LoMenzo began her professional career in
television, working in New York City, as a news editor for ABC-TV's
Good Morning America and as associate producer at CBS News. She
received an Emmy nomination while at WABC-TV for her work as
special projects producer. A graduate of New York University, she
resides in Richmond. About Insmed Insmed is a biopharmaceutical
company focused on the development and commercialization of drugs
for the treatment of metabolic diseases and endocrine disorders
with unmet medical needs. For more information, please visit
www.insmed.com. Forward Looking Statements Statements included
within this press release, which are not historical in nature, may
constitute forward-looking statements for the purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements regarding the pending litigation and
or future ability to conduct our business as now conducted and as
it is currently proposed to be conducted. Such forward-looking
statements are subject to numerous risks and uncertainties,
including but not limited to the uncertainty of the outcome of any
litigation with Tercica, the risk that product candidates may fail
in the clinic or may not be successfully marketed or manufactured,
the company may lack financial resources to complete development of
product candidates or the FDA or other regulatory agencies may
interpret the results of our studies differently than we have. We
can give no assurances that we would be successful in any
litigation or that such litigation would not have a material
adverse effect on our business, financial condition and results of
operation. Furthermore, we may not be able to afford the expense of
defending against such a claim. As a result of these and other
risks and uncertainties, actual results may differ materially from
those described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Août 2023 à Août 2024